Acute Phase Reactant in Non-COVID-19 Bacterial Pneumonia

• ClinicalTrials.gov Identifier: NCT05926089
• Recruitment Status: Completed
• First Posted: July 3, 2023
• Last Update Posted: July 14, 2023
• Sponsor: Cairo University
• Information provided by (Responsible Party): Eman Kamal Ibrahim Hassan, Cairo University

Study Description

Brief Summary:

This study is a cross-sectional study, was conducted at Chest department of Kasr Al-ainy Hospital, Cairo university during the period between October 2020 and April 2021.

The aim of the work was to evaluate levels of acute phase reactants(APR) in Non-COVID-19 bacterial pneumonia, and to correlate between levels of APR and the disease severity.

Condition or disease	Intervention/treatment
Pneumonia; Acute-Phase Reaction	Diagnostic Test: Blood sampling

Detailed Description:

51 patients were included in our study, diagnosed as Non-COVID pneumonia

Inclusion criteria:

1. PCR(polymerase chain reaction) negative for COVID.
2. All patients of both sexes with pneumonia .

Exclusion criteria:

1. Non pulmonary infections.
2. Post surgery patients.
3. Renal patients.
4. hepatic patients.
5. Cardiac patients.
6. Recent pulmonary embolism.

Methodology in details:

All patients were subjected to:

1. Full history with emphasis on:

   • Epidemiological features (age, gender).
   • Risk factors (smoking, DM).
   • Clinical presentation (cough, Fever and duration of illness).
2. Clinical examination (local chest examination).
3. Laboratory investigations: venous blood samples were taken to measure APR

Study Design

• Study Type: Observational
• Actual Enrollment: 51 participants
• Observational Model: Case-Only
• Time Perspective: Cross-Sectional
• Official Title: Acute Phase Reactant in Non-COVID-19 Community Acquired Pneumonia
• Actual Study Start Date: October 1, 2020
• Actual Primary Completion Date: April 30, 2021
• Actual Study Completion Date: May 30, 2021

Groups and Cohorts

Intervention Details:

• Diagnostic Test: Blood sampling
  blood sampling to measure APR

Outcome Measures

Primary Outcome Measures :

1. measurement of APR levels in non-Covid-19 pneumonia [ Time Frame: 6 months ]
   assessment of the level of APR and its relation to disease severity

Biospecimen Retention:   Samples Without DNA

• Complete blood picture, differential leucocytic count and platelets count: Done by The newly developed automated hematology analyzer (Sysmex, Kobe, Japan) enumerates and classifies blood cells by a combination of direct current detection and flow cytometry. (Daves et al., 2015).

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 75 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No
• Sampling Method: Probability Sample

Study Population

All patients( 51 patients diagnosed as non-COVID19 Pneumonia) were subjected to:

1. Full historywith emphasis on:

   • Epidemiological features .
   • Risk factors (smoking, DM).
   • Clinical presentation (cough, Fever and duration of ilness).
2. Clinical examination (local chest examination).
3. Laboratory investigations: venous blood samples were taken for:• Complete blood picture, differential leucocytic count and platelets count, ESR ,CRP, d-dimer and ferritin

Criteria

Inclusion Criteria:

• COVID-19 negative bacterial pneumonia

Exclusion Criteria:

• COVID-19 positive
• other non-pulmonary infections

Contacts and Locations

Locations

Egypt

Kasr alainy school of medicine

Cairo, Egypt, 11562

Sponsors and Collaborators

Cairo University

More Information

• Responsible Party: Eman Kamal Ibrahim Hassan, Assistant Professor of pulmonology, Cairo University
• ClinicalTrials.gov Identifier: NCT05926089
• Other Study ID Numbers: MS-358-2020
• First Posted: July 3, 2023
• Last Update Posted: July 14, 2023
• Last Verified: July 2023

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Pneumonia; Acute-Phase Reaction; Respiratory Tract Infections; Infections; Lung Diseases; Respiratory Tract Diseases; Inflammation; Pathologic Processes